Eurocine Vaccines resolves on scientific advice with the Swedish Medical Products Agency ahead of clinical trial application
The Board of Directors of Eurocine Vaccines has resolved to request scientific advice from the Swedish Medical Products Agency ahead of submitting the clinical trial application with the company’s vaccine candidate against chlamydia. The scientific advice aims to strengthen Eurocine Vaccines´ documentation and maximize the probability of a swift approval of the application. As a consequence, Eurocine Vaccines plans to initiate the clinical study in the first half-year 2023.
Prior to the clinical study with the vaccine candidate against chlamydia, a scientific advice will be